Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: "Ocera Therapeutics, Inc." (OCRX) Report Updated: Feb 01, 2016 | Print This Page

Get more stock ratings by Louis Navellier

"Ocera Therapeutics, Inc." (OCRX)

Rating: Sell Volatility: Moderate
Total Grade: D Industry: Pharmaceuticals
Competitors: HSKA, NVO, PBH, TXMD

Stock Analysis

Rating: Monthly View

February March April May June July August September October November December January

Rating: Weekly View

This Week: D down no change
Last Week: D same upgrade
Two Weeks Ago: F up no change
service keys

"Ocera Therapeutics, Inc."© quotemedia

Company Profile

Ocera Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics for liver and gastrointestinal diseases. Its product pipeline includes OCR-002 (ornithine phenylacetate), an injectable ammonia scavenger for the treatment and prevention of hyperammonemia and resultant acute hepatic encephalopathy in patients with liver cirrhosis and acute liver failure; and Zysa, a microspherical carbon adsorbent with selective adsorption profile for various unwanted substances/toxins involved in the pathology of liver and gastrointestinal diseases. Ocera Therapeutics, Inc. was incorporated in 2004 and is based in San Diego, California.

Recent News: "Ocera Therapeutics, Inc."